An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2016
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer; Medulloblastoma; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 23 Sep 2016 Results of pooled analysis of this and other three studies on patients and four on volunteers published in the European Journal of Clinical Pharmacology (2016).
- 20 Apr 2016 Results of PK analysis of BOLT study and pooled analysis of other three studies including this published in the Journal of Clinical Pharmacology
- 29 Aug 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record